Antibody-mediated EGF receptor blockade as an anticancer therapy: From the laboratory to the clinic

Cancer Immunology, Immunotherapy

Volumn 52, Issue 5, 2003, Pages 342-346

  Mendelsohn, John ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225; MONOCLONAL ANTIBODY 528; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

EID: 0038290555     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0354-7     Document Type: Conference Paper

References (67)

1. Mendelsohn J (2000) Blockade of receptors for growth factors: an anti-cancer therapy. Clin Cancer Res 6:747
2. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(18s):1s
3. Cohen S (1962) Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem 237:1555
4. Cohen S, Carpenter G, King L Jr (1980) Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255:4834
5. Barnes D. Sato G (1980) Serum-free cell culture: a unifying approach. Cell 22:649
6. Cooper JA, Hunter T (1981) Similarities and differences between the effect of epidermal growth factor and Rous sarcoma virus. J Cell Biol 91:878
7. Chinkers M, Cohen S (1981) Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature 290:516
8. Erickson E, Shealy DJ, Erickson RL (1981) Evidence that viral transforming gene products and epidermal growth factor stimulate phosphorylation of the same cellular protein with similar specificity. J Biol Chem 256:11381
9. Sporn MB, Todaro GJ (1980) Autocrine secretion and malignant transformation of cells. N Engl J Med 303:878
10. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B (1986) Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149:9
11. Mendelsohn J, Baselga J (1995) Antibodies to growth factors and receptors. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. JB. Lippincott, Philadelphia, 607
12. Holley RW (1975) Control of growth of mammalian cells in cell culture. Nature 258:487
13. Pardee AB (1989) G1 events and regulation of cell proliferation. Science 246:603
14. Wilkin T (1990) Receptor autoimmunity in endocrine disorders. N Engl J Med 323:1318
15. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495
16. Kawamoto TK, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J (1983) Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80:1337
17. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH (1983) Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511
18. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J (1984) Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755
19. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002
20. Fan Z, Mendelsohn J, Masui H, Kumar R (1993) Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem 268:21073
21. Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595
22. Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J (1991) Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97
23. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311
24. Waterfield MD, Mayes ELV, Stroobant P, Bennett PLP, Young S, Goodfellow PN, Banting GS, Ozanne B (1982) A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem 20:149
25. Schreiber AB, Libermann TA, Lax I, Yarden Y, Schlessinger J (1983) Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem 258:846
26. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD (1984) Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences. Nature 307:521
27. Xu YH, Ishii S, Clark AJ, Sullivan M, Wilson RK, Ma DP, Roe BA, Merlino GT, Pastan I (1984) Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature 309:806
28. Lin CR, Chen WS, Kruiger W, Stolarsky LS, Weber W, Evans RM, Verma IM, Gill GN, Rosenfeld MG (1984) Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 224:843
29. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J (1984) Human epidermal growth factor receptor cRNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418
30. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. (1988) Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605
31. Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamine dichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637
32. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327
33. Baselga J, Norton L, Coplan K, Shalaby R, Mendelsohn J (1994) Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 35:A2262
34. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G (1999) Antitumor activity of sequential treatment with Topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909
35. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935
36. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701
37. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110
38. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies. J Clin Oncol 19:3267
39. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:1235
40. Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese J (2002) A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 21:95
41. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024
42. Rusnak DW, Affleck K, Gilmer TM, Jowett A, Lackey K, Spector N, Xia W (2001) The effects of the novel EGFR/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and transformed cell lines. Proc Am Assoc Cancer Res 42:4309
43. Zinner RG, Nemunaitis J, Donato NJ, Shin HC, Myers JN, Zhang PS, Zentgraft RE, Lee JJ, Khuri FR, Glisson BS, Eiseman I, Olson SC, Bycott P, Lenehan PF, Hong WK, Shin DM (2001 A phase 1 clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors: Clin Cancer Res 7:3767s
44. Mendelsohn J, Baselga J (2003) Status of EGF-receptor antagonists in the biology and treatment of cancer. J Clin Oncol (in press)
45. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397
46. 1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666
47. Mandal M, Adam L, Mendelsohn J, Kumar R (1998) Nuclear targeting of Bax during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells. Oncogene 17:999
48. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z (2000) Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 82:1991
49. Petit AM. Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523
50. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257
51. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin Cancer Res 6:1936
52. Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62:4300
53. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM (1993) Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37:343
54. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904
55. Baselga J, Averbuch SD, (2000) ZD1839 ('Iressa') as an anticancer agent. Drugs 60:33
56. Drebin JA, Link VC, Weinberg RA, Greene MI (1986) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83:9129
57. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165
58. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707
59. HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J Clin Oncol 14:737
60. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 344:783
61. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59:1236
62. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Muser M, Knecht R (2001) Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 47:519
63. Crombet T, Osorio M (2002) Cruz T. Figueredo R. Koropatnick J. Reginfo E. Torres O. Perez R. Lage A. Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer. Proc Am Soc Clin Oncol 21:53
64. Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S (1995) In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer 72:928
65. Pfister DG, Lipton A, Belt R, Motzer RJ, Winston C, Metz EM, Sherman EJ, Curnow RT (1999) A phase I trial of the epidermal growth gactor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol 18:1667
66. Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM (1997) Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. J Immunol 158:872
67. Saltz L, Rubin M, Hochster H, Tchekmevdian NS, Waksal H, Needle M, LoBuglio AF (2001) Cetuximab (IMC-225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:7